Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1991 1
1992 1
1993 3
1994 4
1995 8
1996 5
1997 7
1998 5
1999 19
2000 18
2001 22
2002 25
2003 25
2004 26
2005 26
2006 34
2007 39
2008 41
2009 58
2010 50
2011 47
2012 52
2013 58
2014 69
2015 70
2016 68
2017 68
2018 67
2019 86
2020 112
2021 117
2022 133
2023 107
2024 116
2025 109

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,488 results

Results by year

Filters applied: . Clear all
Page 1
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, Zugazagoitia J, Kim YJ, Chiu CH, Kim SW, Nadal E, Gil-Bazo I, Murphy SP, Anderson BG, Xia Y, Wang G, Bauml JM, Chioda M, Simoes J, Mahadevia PJ, Lopes G. Spira AI, et al. Among authors: chiu ch. J Thorac Oncol. 2025 Jun;20(6):809-816. doi: 10.1016/j.jtho.2025.01.018. Epub 2025 Jan 24. J Thorac Oncol. 2025. PMID: 39864547 Free article. Clinical Trial.
Never Say No to Never-Smokers.
Chiu CH, Yang PC. Chiu CH, et al. J Thorac Oncol. 2023 Jun;18(6):689-693. doi: 10.1016/j.jtho.2023.03.010. J Thorac Oncol. 2023. PMID: 37210179 Free article. No abstract available.
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Stevenson K, Susick L, Latack K, Daniel J, Chiou C, Divine GW, Ghazyaran V, Pogue JM. Kaye KS, et al. Among authors: chiu ch. NEJM Evid. 2023 Jan;2(1):10.1056/evidoa2200131. doi: 10.1056/evidoa2200131. Epub 2022 Dec 6. NEJM Evid. 2023. PMID: 37538951 Free PMC article.
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.
Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH, Wu YC, Chen CY, Hsu HH, Wu MT, Yang CT, Chong IW, Lin YC, Hsia TC, Lin MC, Su WC, Lin CB, Lee KY, Wei YF, Lan GY, Chan WP, Wang KL, Wu MH, Tsai HH, Chian CF, Lai RS, Shih JY, Wang CL, Hsu JS, Chen KC, Chen CK, Hsia JY, Peng CK, Tang EK, Hsu CL, Chou TY, Shen WC, Tsai YH, Tsai CM, Chen YM, Lee YC, Chen HY, Yu SL, Chen CJ, Wan YL, Hsiung CA, Yang PC; TALENT Investigators. Chang GC, et al. Among authors: chiu ch. Lancet Respir Med. 2024 Feb;12(2):141-152. doi: 10.1016/S2213-2600(23)00338-7. Epub 2023 Nov 29. Lancet Respir Med. 2024. PMID: 38042167
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: chiu ch. J Thorac Oncol. 2025 Apr;20(4):487-499. doi: 10.1016/j.jtho.2024.11.032. Epub 2024 Nov 30. J Thorac Oncol. 2025. PMID: 39622410 Free article. Clinical Trial.
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, Krebs MG, Liu SV, John T, Otterson GA, Tan DSW, Patil T, Dziadziuszko R, Massarelli E, Seto T, Doebele RC, Pitcher B, Kurtsikidze N, Heinzmann S, Siena S. Drilon A, et al. Among authors: chiu ch. JTO Clin Res Rep. 2022 Apr 29;3(6):100332. doi: 10.1016/j.jtocrr.2022.100332. eCollection 2022 Jun. JTO Clin Res Rep. 2022. PMID: 35663414 Free PMC article.
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.
Wu YL, Kim HR, Soo RA, Zhou Q, Akamatsu H, Chang GC, Chiu CH, Hayashi H, Kim SW, Goto Y, Kato T, Zhou J, Lee VH, Nishio M, Han B, Kim DW, Lu S, Polli A, Martini JF, Toffalorio F, Wong CH, Mok T. Wu YL, et al. Among authors: chiu ch. J Thorac Oncol. 2025 Jul;20(7):955-968. doi: 10.1016/j.jtho.2025.02.021. Epub 2025 Feb 28. J Thorac Oncol. 2025. PMID: 40024442 Free article. Clinical Trial.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. Rudin CM, et al. Among authors: chiu ch. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17. J Clin Oncol. 2024. PMID: 37976444 Free PMC article. Clinical Trial.
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Jänne PA. Wang M, et al. Among authors: chiu ch. Cancer Discov. 2022 Jul 6;12(7):1676-1689. doi: 10.1158/2159-8290.CD-21-1615. Cancer Discov. 2022. PMID: 35404393 Free PMC article.
1,488 results